Dr Pretoria Bilinski
Medical Oncologist and Palliative Care Physician
Greenslopes
Dr Pretoria Bilinski a medical oncology and palliative care physician with more than 30 years’ experience as a medical doctor with 25+ years exclusively delivering care to cancer patients and the terminally ill.
Her areas of cancer subspecialty include breast, prostate, and lung cancer (including mesothelioma).
Dr Pretoria Bilinski
MBBS FRACP MPallC FAChPM MHA
Medical Oncologist and Palliative Care Physician
Dr Pretoria Bilinski
MBBS FRACP MPallC FAChPM MHA
Oncology, Breast Cancer, Medical Oncology, Palliative Care
Dr Pretoria Bilinski a medical oncology and palliative care physician with more than 30 years’ experience as a medical doctor with 25+ years exclusively delivering care to cancer patients and the terminally ill.
Her areas of cancer subspecialty include breast, prostate, and lung cancer (including mesothelioma).
About Dr Bilinski
Dr Pretoria Bilinski a medical oncology and palliative care physician with more than 30 years’ experience as a medical doctor with 25+ years exclusively delivering care to cancer patients and the terminally ill.
Her areas of cancer subspecialty include breast, prostate, and lung cancer (including mesothelioma). She attends several tumour board meetings each week where she networks with colleagues to deliver multidisciplinary personalised patient care. She is involved in clinical trials providing patients access to gold standard and emerging therapies.
She has extensive experience in providing symptom management, palliative and terminal care to patients with progressive chronic illness and advanced incurable cancers. Since the start of the legislation, 01/01/2023 in Queensland, she is an authorised voluntary assisted dying (VAD) practitioner.
Dr Bilinski works exclusively at Greenslopes Private Hospital. Working at one campus has afforded her the ability to create a wonderful working relationship with the ward staff, allied health professionals and medical colleagues.
Additionally, she volunteers her time with the College (RACP) and university (UQ) as an examiner to support the current candidates and next generation of medical students and junior doctors.
Patient Information
Under the Health Insurance Legislation a referral is required for all consultation and treatments provided. Referrals are required for reimbursement from Medicare.
Referrals from other specialists are valid for a three month period from the time of initial consultation; referrals from general practitioners are valid for a twelve month period from the date of issue.
It is the patients’ responsibility to ensure that referrals are current for all appointments and treatment.
Her practice is exclusively bulkbill and no gap. It has been since the start, 2009.
Patients who receive payouts for the treatment of mesothelioma will be billed at the same rates but must inform the practice manager so that their bills can be prepared in a timely manner.
Whilst Dr Bilinski is happy to consult public patients in her private practice and offer a second opinion regarding their management, in order to have ongoing treatment under her care patients are required to have private health insurance in order to access care at Greenslopes Private Hospital.
Scroll down for Consultations, What to bring, Procedures and Costs.
Open Clinical Trials
SI BMS IM043-004 Phase I BMS-986360/CC-90001 alone and in combination with chemotherapy or Nivolumab in advanced solid tumours. 01/2023
SI Skyscraper-15 A phase III randomised, double blind study of Tiragolumab plus Atezolizumab compared with placebo plus Atezolizumab in participants with completely resected stage IIB, IIIA, or IIIB PDL1 positive Non small cell lung cancer who have received adjuvant platinum-based chemotherapy. (04/2024)
SI TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy. (10/2024)
SI Randomized, Double-Blind, Multicentre Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001)(03/2025)
SI CA071-1000: A phase 3, Two Part, Randomized, open label, Adaptive study comparing BMS-986265 verses Investigator’s Choie of Therapy Comprising either Docetaxel or Second Androgen Receptor Pathway Inhibitor ARPI in participants with metastatic castration-resistance Prostate cancer (mCRPC0 -rechARge (03/2025)
SI A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49% (05/2025)
Closed Clinical Trials
SI. Marquee ARQ 197-A-U302 A phase III, randomized, double-blinded, placebo-controlled study of ARQ 197 plus Erlotinib verses placebo plus Erlotinib in previously treated subjects with locally advanced or metastatic, non-squamous, non-small cell lung cancer. 06/2011 (CLOSED)
SI. Bionomics GU 09-145 Phase I/II study of BNC105P in combination with Everolimus or following Everolimus for progressive metastatic clear cell renal cell carcinoma following prior TKI. 08/2011. (CLOSED)
PI. Merck EMR 100070-004 Phase III open labelled multicentre Avelumab Vs docetaxel after progression with platinum based chemotherapy in NSCLC. 09/2015 (CLOSED)
PI. Merck EMR 100070-005 Phase III open labelled multicentre Avelumab Vs platinum based doublet as first line treatment of recurrent or stage IV PDL1+ NSCLC. 03/2016 (CLOSED)
PI AstraZeneca PROfound trial A phase III, open-label, randomized study to assess the efficacy and safety of Olaparib (Lynparza) verses Enzalutamide or Abiraterone acetate in men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations. 01/2017 (CLOSED)
SI. Merck EMR 200647-001 A phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumours and expansion to selected indications. (09/2016) (CLOSED)
PI AstraZeneca PROpel trial A randomized, double-blind, placebo-controlled, multicentre phase III study of Olaparib plus Abiraterone relative to Placebo plus Abiraterone as First-line therapy in men with metastatic castration-resistance prostate cancer. 09/2018 (CLOSED)
SI. Merck MK MK-2475-495 A phase II precision oncology study of biomarker-directed, Pembrolizumab based combination for advanced non-small cell lung cancer. 04/2019 (CLOSED)
PI Merck. Keynote 641. A phase III, randomized, double-blind trial of Pembrolizumab plus Enzalutamide verses placebo plus Enzalutamide in participants with metastatic castration-resistant prostate cancer. 08/2019 (CLOSED)
SI. BMS. CA209-73L A phase III, randomized, open label study to compare Nivolumab Plus concurrent chemoradiotherapy followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT followed by Nivolumab Vs CCRT followed by Durvalumab in previously untreated, locally advanced non-small cell lung cancer 12/2019 (CLOSED)
SI. Merck. MK3475-991 A phase III, randomized, doubled blind trial of Pembrolizumab (MK3475) Plus Enzalutamide Plus ADT verses Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone sensitive prostate cancer. 03/2020 (CLOSED)
SI. BMS. CA001-050 A randomized, open-label Phase II clinical trial of BMS-986012 in combination with carboplatin, etoposide, and Nivolumab as first-line therapy in extensive stage small cell lung cancer. 04/2021 (CLOSED)
SI. Pfizer. Talapro-3. A phase III, randomised, double blind study of Talazoparib with Enzalutamide verses Placebo with Enzalutamide in men with DDR Gene Mutated metastatic castration-sensitive prostate cancer. 12/2021 (CLOSED)
SI AstraZeneca CAPitello 280 A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer 07/2022 (CLOSED)
SI Gilead EVOKE 01 Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy 12/2022 (CLOSED)
SI A phase3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab Vs Durvalumab Alone in subjects with Extensive-Stage Small-Cell Lung cancer following Platinum, Etoposide and Durvalumab (DeLLphi-305) (08/2024) (CLOSED)
Contact Us
-
Suite 206 Ramsay Specialist Centre
212 Newdegate Street
Greenslopes
4120 - 07 38479901
- 07 38479902
- PO Box 473 Cannon Hill 4170
- janelle@altuss.com.au (Practice Manager)